Hypogammaglobulinemia at Leukapheresis Predicts Delayed Humoral Immune Reconstitution and Increased Risk of Infections After CD19 CAR-T for B-Cell Lymphoma
Hypogammaglobulinemia at leukapheresis is a simple yet informative biomarker that predicts delayed humoral immune recovery, increased infectious events, and treatment-related mortality after CD19 CAR-T therapy in B-cell lymphoma. Moreover, it represents an independent risk factor for post-CD19 CAR-T infections, separate from neutrophil and lymphocyte recovery.
Authors
- Aya Nishida
- Kosei Kageyama (ORCID: https://orcid.org/0000-0003-1826-3127)
- Shinsuke Takagi
- Yuki Taya
- Atsushi Wake
- Kyosuke Yamaguchi (ORCID: https://orcid.org/0000-0002-8238-8672)
- Yuki Asano-Mori
- Hisashi Yamamoto
- Tatsuro Hirao
- Daisuke Kaji
- Naoyuki Uchida
- Mika Kuno
- Go Yamamoto
- Otoya Watanabe
Institutions
- Toranomon Hospital (JP)
Publication Details
- Journal
- Transplantation and Cellular Therapy
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.jtct.2026.02.046
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00